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Background: In this study, we report on the synthesis, radiolabeling, and biological evaluation of two new
somatostatin-14 (SS14) analogs, modified with the universal chelator DOTA. We were interested to investigate if and
to what extent such radiotracer prototypes may be useful for targeting sst1-5-expressing tumors in man but, most
importantly, to outline potential drawbacks and benefits associated with their use.
Methods: AT1S and AT2S (DOTA-Ala1-Gly2-c[Cys3-Lys4-Asn5-Phe6-Phe7-Trp8/DTrp8-Lys9-Thr10-Phe11-Thr12-Ser13-Cys14-
OH], respectively) were synthesized on the solid support and labeled with 111In. The sst1-5 affinity profile of AT1S/AT2S
was determined by receptor autoradiography using [Leu8,DTrp22,125I-Tyr25]SS28 as radioligand. The ability of AT2S to
stimulate sst2 or sst3 internalization was qualitatively analyzed by an immunofluorescence-based internalization assay
using hsst2- or hsst3-expressing HEK293 cells. Furthermore, the internalization of the radioligands [
111In]AT1S and [111In]
AT2S was studied at 37 °C in AR4-2J cells endogenously expressing sst2. The in vivo stability of [
111In]AT1S and [111In]
AT2S was tested by high-performance liquid chromatography analysis of mouse blood collected 5 min after
radioligand injection, and biodistribution was studied in normal mice. Selectively for [111In]AT2S, biodistribution was
further studied in SCID mice bearing AR4-2J, HEK293-hsst2A
+ , -hsst3
+ or -hsst5
+ tumors.
Results: The new SS14-derived analogs were obtained by solid phase peptide synthesis and were easily labeled with
111In. Both SS14 conjugates, AT1S, and its DTrp8 counterpart, AT2S, showed a pansomatostatin affinity profile with the
respective hsst1-5 IC50 values in the lower nanomolar range. In addition, AT2S behaved as an agonist for sst2 and sst3
since it stimulated receptor internalization. The 111In radioligands effectively and specifically internalized into
rsst2A-expressing AR4-2J cells with [
111In]AT2S internalizing faster than [111In]AT1S. Ex vivo mouse blood analysis
revealed a rapid degradation of both radiopeptides in the bloodstream with the DTrp8 analog showing higher stability.
Biodistribution results in healthy mice were consistent with these findings with only [111In]AT2S showing specific
uptake in the sst2-rich pancreas. Biodistribution of [
111In]AT2S in tumor-bearing mice revealed receptor-mediated
uptake in the AR4-2J (1.82± 0.36 %ID/g - block 0.21± 0.17 %ID/g at 4 h post injection (pi)), the HEK293-hsst2A
+
(1.49 ± 0.2 %ID/g - block 0.27± 0.20 %ID/g at 4 h pi), the HEK293-hsst3
+ (1.24 ± 0.27 %ID/g - block 0.32± 0.06 %ID/g at
4 h pi), and the HEK293-hsst5
+ tumors (0.41 ± 0.12 %ID/g - block 0.22± 0.006 %ID/g at 4 h pi). Radioactivity washed out
from blood and background tissues via the kidneys.
Conclusions: This study has revealed that the native SS14 structure can indeed serve as a motif for the development
of promising pansomatostatin-like radiotracers. Further peptide stabilization is required to increase in vivo stability and,
consequently, to enhance in vivo delivery and tumor targeting.
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Somatostatin-14 (SS14) is a native peptide hormone
exerting a variety of physiological actions in the brain
and in peripheral tissues after binding to high affinity
receptors on the cell membrane of target cells [1-3].
Somatostatin receptors comprise five subtypes (sst1-5)
and are also found in many human tumors where they
are expressed alone or in various combinations [4-7].
Accordingly, they can serve as molecular targets for
therapeutic interventions with somatostatin analogs.
Native SS14 binds with nanomolar affinity to all five
human receptor subtypes, hsst1-5, but its use for drug
development is prevented by its poor in vivo stability
[8]. This problem has been competently addressed by
the advent of synthetic somatostatin analogs tailored to
withstand enzymatic attack in vivo, such as octreotide
(SMS 201–995, Sandostatin) [9] or Lanreotide (BIM
23014, Somatuline) [10]. Despite their higher potency
and longer duration of action, these cyclic-octapeptide
analogs have inadvertently become sst2-preferring and
have lost most of somatostatin’s affinity for the other
subtypes. Yet, they have been used with success in the
treatment of acromegaly and sst2-expressing tumors
[11,12].
In a rather recent approach, metabolically stabilized
somatostatin analogs have been functionalized with
metal chelators to accommodate radiometals useful for
diagnostic imaging and radionuclide therapy [13].
[111In-DTPA]octreotide (OctreoScanW) is the first
approved sst2-avid peptide radiopharmaceutical. When
administered in patients, it localizes in primary and
metastatic sst2
+-lesions, which can be efficiently visua-
lized with the aid of an external imaging device [14].
Following OctreoScanW, several other sst2-seeking
radiopeptides, suitable for SPECT (99mTc-, 111In-,
67 Ga-labeled), PET (68Ga-, 64Cu-labeled), or radio-
nuclide therapy (90Y- or 177Lu-labeled) have been eval-
uated in animal models and in patients with
neuroendocrine tumors (NETs) [15-19].
In all above instances, the sst2 subtype prevails in inci-
dence and density of expression allowing the successful
application of sst2-preferring radioligands. However, it
should be stressed that, despite the predominance of sst2
expression in many human tumors, co-expression of sst2
with other sst1-5 subtypes is frequent enough. Thus, sst2
and sst5 are expressed often together in GH-secreting pi-
tuitary adenomas, and various combinations of ssts, such
as sst2 and sst1, are expressed in gastroenteropancreatic
(GEP)-NETs.
Moreover, a number of human tumors devoid of sst2
may instead express one or more of the other sst1-5
[6,7,15,20-22]. For example, ductal pancreatic carcin-
omas or primary hormone-sensitive prostate cancers are
reported to often express sst1 [23-26]. Hence, the use ofpansomatostatin-like agents will broaden the clinical
indications and will increase the diagnostic/therapeutic
efficacy of currently available sst2-preferring (radio)
peptides.
SOM230 and KE108 are two multi-somatostatin re-
ceptor ligands that have been developed to improve
somatostatin analog-based therapy. SOM230 has high
affinity for sst1-3 and sst5 [27], while KE108 has high af-
finity for all five sst1-5 [28]. However, the absence of sst2
internalization may turn out to be a serious disadvantage
of SOM230- or KE108-based radioligands compromising
their accumulation in target cells, in the most frequent
cases where sst2 expression prevails [29-32]. On the
other hand, well sst2-internalizing and multi-sst2-/sst3-/
sst5-binding analogs, such as DOTA-NOC [33], will miss
sst1-expressing tumors. Thus, a pansomatostatin affinity
profile and the preservation of important pharmaco-
logical traits, especially sst2 internalization, seem to rep-
resent an advantageous combination for enhancing the
efficacy of sst1-5-targeting radioligands.
In this respect, the parent SS14 motif has drawn our at-
tention despite its suboptimal metabolic stability [8]. In fact,
not much is reported on the in vivo performance of radio-
peptides based on SS14. In a previous study, 111In-[DTPA,
DAla1,DTrp8,Tyr11]SS14 showed specific and comparable
to OctreoScanW accumulation in physiological sst2-rich tis-
sues in mice [34], implying that SS14-based radioligands
may indeed possess sufficient in vivo stability to successfully
reach their target while still able to internalize via the sst2.
In this study, we have coupled the universal chelator
DOTA to Ala1 of SS14 (AT1S). In this way, labeling
options beyond 111In are feasible while N-terminal cap-
ping of SS14 is also achieved, a method known to pro-
long the biological half-life of peptides. In the second
analog, AT2S, Trp8 was replaced by DTrp8 to further en-
hance stability [35]. This modification is also reported to
improve sst2 affinity by favoring the β-turn structure for
several cyclic somatostatin analogs [36]. Detailed bio-
logical characterization of the AT1S prototype and its
DTrp8 analog, AT2S, is presented herein encompassing
in vitro binding affinity and functional assays in sst1-5-
expressing cells, metabolic studies, and biodistribution
of 111In-radioligands in mice bearing sst2
+, sst3
+, and sst5
+
tumors. This comprehensive study will provide the basis
for structural interventions on the AT1S motif towards
improved pansomatostatin-like radiopeptides with ad-
vantageous key pharmacological features, such as a pre-
served sst2-internalization capacity.
Methods
Chemistry
General
All chemicals were reagent grade and used without fur-
ther purification. The protected chelator 2-(4,7,10-tris(2-
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1-yl)acetic acid (DOTA-tris(tBu)ester) was supplied by
CheMatech (Dijon, France). The L-amino acid precur-
sors, Fmoc-Ala-OH, Fmoc-Gly-OH, Fmoc-Cys(Trt)-OH,
Fmoc-Lys(Boc)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Phe-
OH, Fmoc-Trp(Boc)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Ser
(tBu)-OH, and the D-amino acid precursor, Fmoc-DTrp
(Boc)-OH and H-L-Cys(Trt)-2-Chlorotrityl resin (substi-
tution 0.55 mmol/g) that was used in solid-phase pep-
tide synthesis (SPPS), were purchased from CBL (Patras,
Greece). [Tyr3]octreotate (Tate, H-DPhe-c[Cys-Tyr-
DTrp-Lys-Thr-Cys]-Thr-OH) and Demopan 2 (DP2, N4-
Tyr-c[DDab-Arg-Phe-Phe-DTrp-Lys-Thr-Phe]) used for
in vitro and/or in vivo receptor blockade were synthe-
sized as previously described [31,37]. Final purifications
were conducted on a semi-preparative high-performance
liquid chromatography (HPLC) system Mod.10 ÄKTA
from Amersham Biosciences (Piscataway, NJ, USA) on a
Supelcosil C18 (5 μm, 8 × 250 mm) by Sigma Aldrich
(St. Louis, MO, USA). Electrospray ionization-mass
spectrometry, on a micromass-platform LC instrument
by Waters Micromass Technologies (Milford, MA, USA)
was used to identify the products. Indium chloride
(111InCl3) was purchased from Biomedica Life Sciences
SA (Athens, Greece). Radiochemical HPLC analyses
were performed on a Waters chromatograph (Waters,
Vienna, Austria) with a 600E multi-solvent delivery sys-
tem coupled to twin detection instrumentation compris-
ing a Waters 2998 photodiode array UV detector and a
Gabi γ-detector (Raytest, RSM Analytische Instrumente
GmbH, Germany). Data processing and chromato-
graphic control were conducted using the Empower soft-
ware. Analyses were performed on an XTerra RP-18
(5 μm, 4.6 × 150 mm) cartridge column (Waters, Ger-
many) and on a Symmetry Shield RP-18 (5 μm,
3.9 × 20 mm) column (Waters, Germany). Radioactivity
measurements were conducted in an automated well-
type γ-counter (NaI(Tl) crystal, Canberra Packard Auto-
Gamma 5000 series model, Schwadorf, Austria) cali-
brated for 111In.
Synthesis of conjugates
SPPS was performed using the standard 9-fluorenyl-
methoxycarbonyl (Fmoc)/tert-butyl (tBu) methodology. The
AT1S and AT2S amino acid sequences (DOTA-Ala1-Gly2-
Cys3-Lys4-Asn5-Phe6-Phe7-Trp8-Lys9-Thr10-Phe11-Thr12-
Ser13-Cys14-OH and DOTA-Ala1-Gly2-Cys3-Lys4-Asn5-
Phe6-Phe7-DTrp8-Lys9-Thr10-Phe11-Thr12-Ser13-Cys14-OH,
respectively) were assembled on H-L-Cys(Trt)-2-Chlorotri-
tyl resin (substitution 0.55 mmol/g). Coupling of each
amino acid was performed with a threefold molar excess of
Fmoc-amino acid, using 1-hydroxybenzotriazol (HOBt)
(4.5-fold molar excess) and N,N′-diisopropylcarbodiimide
(DIC) (3.3-fold molar excess) as activating agents, indimethylformamide (DMF). After a period of 2.5 to 3 h,
the completeness of the reaction was monitored by the
standard ninhydrin test. In case of incomplete coupling,
the coupling procedure was repeated prior to Nα-Fmoc
protecting group removal. Fmoc deprotection was per-
formed by the addition of 25% piperidine in DMF for 15
to 25 min. Finally, DOTA-tris(tBu)ester (threefold molar
excess) was coupled at the N-terminus of the amino acid
chain using HOBt (4.5-fold molar excess) and DIC
(3.3-fold molar excess) in DMF. Removal of lateral chain
protecting groups and cleavage from the resin was
achieved by 4-h incubation in a cleavage cocktail com-
prising TFA:triethylaminosilane (TES):1,2-ethanedithiol:-
anisole:H2O 93:3:2:1:1 v/v/v/v/v. The cleavage mixture
was evaporated, and the free peptide conjugates were
precipitated with diethyl ether and filtered. The crude
peptides were dissolved in AcOH-H2O 4:1 to a final
concentration of 2 mg/mL, and iodine (10-fold molar
excess) was added in one portion. The reaction mixture
was left to react for 15 to 25 min at 25 °C. After the oxi-
dation was complete, as indicated by the Ellmann test
and HPLC monitoring, the reaction was quenched by
diluting to twice the volume with H2O, and the iodine
was extracted in CCl4. The aqueous phase was lyophi-
lized, and the products were purified by semi-preparative
HPLC on an RP-C18 support using a linear gradient
from 20% to 60% MeCN (+0.1% TFA, v/v) for 40 min at
a 2-mL/min flow rate. Eluted peptides were lyophilized
immediately. Finally, HPLC analysis was used to moni-
tor the purity of peptides applying two different sys-
tems: (a) HPLC system Mod.10 ÄKTA from Amersham
Biosciences (Piscataway, NJ, USA) with an Alltech
Nucleosil C18 column (5 μm, 4.6 × 250 mm) eluted at a
flow rate of 1 mL/min with a linear gradient of 0% B to
40% B in 40 min, with A = 0.1% TFA (v/v) and
B =MeCN containing 0.1% TFA (v/v) - system A; and
(b) Waters chromatograph with 600E multi-solvent
delivery system coupled to a Waters 2998 photodiode
array UV detector using an RP-18 XTerra (5 μm,
4.6 × 150 mm) cartridge column eluted at a flow rate of
1 mL/min with a linear gradient of 0% B to 60% B in
60 min, with A = 0.1% TFA (v/v) and B = pure MeCN -
system B. Electrospray mass spectrometry (ES-MS) was
conducted in order to confirm formation of the desired
products.
Radiolabeling with 111In
For 111In labeling, 111InCl3 in 50 mM HCl at a 370- to
740-MBq/mL activity concentration was used. Labeling
was conducted by adding 10 nmol AT1S/AT2S analog
per 37 to 74 MBq of 111InCl3 in 0.1 M sodium acetate
buffer and 10 mM sodium ascorbate. Typical end pH
was 4.6. Labeling was completed after incubation in a
boiling water bath for 20 min [13]. Prior to HPLC
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to a final concentration of 1 mM to the labeling reaction
mixture as a ‘free’ 111In3+ scavenger.
Biology
Reagents
All reagents were of best grade available and were
purchased from common suppliers. The sst2-specific
antibody R2-88 was from Agnes Schönbrunn (Houston,
TX, USA), and the sst3-specific antibody (SS-850) was
purchased from Gramsch Laboratories, Schwabhausen,
Germany. The secondary antibody, Alexa Fluor 488 goat
anti-rabbit IgG (H+L), was from Molecular Probes, Inc.
(Eugene, OR, USA). SS14 was provided by Prof. JE Rivier
(The Salk Institute, La Jolla, CA, USA).
Cell lines and animal experiments
The HEK293 cell line expressing the human T7-epitope-
tagged sst2 receptor (HEK-sst2) or the human sst3 or sst5
receptor (HEK-sst3, HEK-sst5) were kindly provided by
S. Schultz (Institute of Pharmacology and Toxicology,
University Hospital, Friedrich Schiller University Jena,
Germany) and cultured as previously described [38,39].
The rat pancreatic tumor cell line AR4-2J endogenously
expressing sst2 was kindly provided by Prof. S. Mather
(St. Bartholomew’s Hospital, London, UK) and cultured
as previously described [37]. All culture reagents were
from Gibco BRL, Life Technologies (Grand Island, NY,
USA) or from Biochrom KG Seromed (Berlin, Germany).
Animal experiments were carried out in compliance
with European and national regulations and were
approved by national authorities. For biodistribution
experiments, in-house male Swiss albino mice (30 ± 5 g)
were used. For experimental tumor models, in-house
SCID mice of 7 weeks of age were used, and the animals
were kept under aseptic conditions until biodistribution
was performed.
Receptor autoradiography for hsst1-5
Cell membrane pellets were prepared from human sst1-
expressing CHO cells, sst2-, sst3-, sst4-expressing CCL39
cells, and sst5-expressing HEK293 cells and stored at
−80 °C. Receptor autoradiography was performed on 20-
μm-thick cryostat (Microm HM 500, Walldorf, Ger-
many) sections of the membrane pellets, mounted on
microscope slides, and then stored at −20 °C as previ-
ously described [39,40]. For each of the tested com-
pounds, complete displacement experiments with the
universal SS28 radioligand [Leu8,DTrp22,125I-Tyr25]SS28
(125I-[LTT]SS28) (74 GBq/mmol; Anawa, Wangen,
Switzerland) using 15,000 cpm/100 μL and increasing
concentrations of the unlabeled peptide ranging from
0.1 to 1,000 nM were performed. As control, unlabeled
SS28 was run in parallel using the same increasingconcentrations. The sections were incubated with 125I-
[LTT]SS28 for 2 h at room temperature in 170 mmol/L
Tris–HCl buffer (pH 8.2), containing 1% BSA, 40 mg/L
bacitracin, and 10 mmol/L MgCl2 to inhibit endogenous
proteases. The incubated sections were washed twice for
5 min in cold 170 mmol/L Tris–HCl (pH 8.2) containing
0.25% BSA. After a brief dip in 170 mmol/L Tris–HCl
(pH 8.2), the sections were dried quickly and exposed
for 1 week to Kodak BioMax MR film (Rochester, NY,
USA). IC50 values were calculated after quantification of
the data using a computer-assisted image processing sys-
tem as described previously [39]. Tissue standards
(Autoradiographic [125I] and/or [14 C] microscales, GE
Healthcare; Little Chalfont, UK) that contain known
amounts of isotope, cross-calibrated to tissue-equivalent
ligand concentrations were used for quantification [39-
42].
Sst2-and sst3-internalization assay
Immunofluorescence microscopy-based internalization
assay for sst2 and sst3 was performed as previously
described [38,43]. HEK-sst2 and HEK-sst3 cells were
grown on poly-DLys (20 μg/mL) (Sigma-Aldrich, St.
Louis, MO, USA) coated 35-mm four-well plates (Cell-
star, Greiner Bio-One GmbH, Frickenhausen, Germany).
Cells were treated for 30 min at 37 °C in growth
medium with increasing concentrations ranging between
1 and 100 nM of either AT2S or SS14 (positive control).
The cells were then rinsed twice with PS (100 mM phos-
phate buffer containing 0.15 M sucrose), fixed and per-
meabilized for 7 min with cold methanol (−20 °C),
rinsed twice with PS, and then blocked for 60 min at
room temperature with PS containing 0.1% BSA. Subse-
quently, the cells were incubated for 60 min at room
temperature with the sst2 specific primary antibody R2-
88 or the sst3 specific primary antibody SS-850, both
diluted 1:1,000 in PS and then washed 3 × 5 min with
PS containing 0.1% BSA. The cells were then incubated
for 60 min at room temperature in the dark with the
secondary antibody Alexa Fluor 488 goat anti-rabbit
IgG (H+ L) diluted in PS (1:600), subsequently washed
3 × 5 min with PS containing 0.1% BSA, and embedded
with PS/glycerol 1:1 and covered with a glass cover slip.
The cells were imaged using a Leica DM RB immuno-
fluorescence microscope (Leica, Deerfield, IL, USA)
and an Olympus DP10 camera (Olympus Corporation,
Shinjuku, Tokyo, Japan).
Radioligand internalization assay
For radioligand internalization experiments, the rsst2-
positive cell line AR4-2J was used. Cells were grown to
confluence for 48 h in six-well plates. On the day of the
experiment, cells were washed twice with ice-cold
internalization medium prepared with F-12-K nutrient
Table 1 Analytical data for AT1S and AT2S
Analog Purity Expected MW (m/z) ES-MS System AatR (min) System B
btR (min)
AT1S 98% 2024.29 - 36.9 41.9
[M+H+] = 2025.29
[M+ 2 H+] / 2 = 1013.14 -
[M+ 3 H+] / 3 = 675.76 675.60 (100)*
AT2S 90% 2024.29 35.8 39.3
[M+H+] = 2025.29
[M+ 2 H+] / 2 = 1013.14 1012.66 (60)*
[M+ 3 H+] / 3 = 675.76 675.72 (40)*
aSystem A and bsystem B are described in the ‘Methods’ section. *Numbers in parenthesis signify relative intensities of peaks in the MS-spectra. MW, molecular
weight.
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The cells were supplied with fresh medium (1.2 mL),
and approximately 300,000 cpm/150 μL [111In]AT1S/
[111In]AT2S (corresponding roughly to 2 pmol total pep-
tide) was added to the medium followed by 0.5% BSAHO
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Table 2 Affinity profile (IC50 in nanomolar) of AT1S and
AT2S for the human sst1-5 receptors
Code hsst1 hsst2 hsst3 hsst4 hsst5
SS14 1.9 ± 0.5 (5) 0.7 ± 0.2 (5) 3.3 ± 1.7 (4) 1.6 ± 0.8 (4) 4.2 ± 0.7 (3)
SS28 2.7 ± 0.5 (3) 2.5 ± 0.1 (3) 2.2 ± 0.6 (3) 2.1 ± 0.4 (3) 2.0 ± 0.2 (3)
AT1S 5.1 ± 1.4 (3) 2.8 ± 0.3 (3) 1.8 ± 0.6 (3) 2.5 ± 0.6 (3) 17 ± 3 (3)
AT2S 14 ± 2 (3) 1.5 ± 0.3 (3) 2.4 ± 0.5 (3) 3.7 ± 0.7 (3) 12 ± 2 (3)
Mean± SEM (numbers in parentheses = number of experiments). The profile
for the human sst1-5 receptors was determined by receptor autoradiography
experiments; [Leu8,DTrp22,125I-Tyr25]SS28 was used as the radioligand and SS14
and SS28 as control compounds.
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5 min at ambient temperature in acid wash buffer
(50 mM glycine buffer with pH 2.8, 0.1 M NaCl). The
supernatant was collected (membrane-bound radioligand
fraction) each time and pooled, and the cells were rinsed
with 0.5% BSA PBS. Cells were lysed by treatment in
1 N NaOH, and cell radioactivity was collected (interna-
lized radioligand fraction). Considering that total activity
comprises membrane-bound plus internalized activity,
the percent internalized activity versus the selected 5-,
15-, 30-, 60-, and 120-min time intervals could be calcu-
lated applying the Microsoft Excel program.
Metabolism in blood
A 150-μL bolus containing [111In]AT1S/[111In]AT2S (11
to 22 MBq, 3 nmol total peptide) was injected in the tail
vein of healthy male Swiss albino mice. The animals
were kept for 5 min in cages with free access to water.
They were sacrificed by cardiac puncture under ether
anesthesia, and blood was withdrawn with a syringe and
immediately placed in a pre-chilled EDTA-containing
polypropylene vial on ice. Blood samples were centri-
fuged at 2,000 × g at 4 °C for 10 min. The supernatant
(>90% radioactivity recovered) was collected, and an
equal volume of MeCN was added. The mixture was
centrifuged for 10 min at 15,000 × g at 4 °C. The super-
natant (>90% recovery of radioactivity) was collected,
and the organic solvent was removed under N2-flux; the
residue was redissolved in physiological saline, passed
through a 0.22-μm Millex-GV filter (Millipore, Milford,
USA) (>90% recovery of radioactivity), and analyzed by
RP-HPLC (>96% radioactivity recovered). For establish-
ing the retention times (tR in min) of parent radiopep-
tides, blood samples were co-injected with the respective
[111In]AT1S or [111In]AT2S and analyzed by RP-HPLC
applying the same conditions.Figure 2 HPLC analysis of [111In]AT2S. Representative radiochromatogra
HPLC. A Symmetry Shield RP18 column was eluted at a flow rate of 1 mL/m
(v/v), and B=MeCN.In vivo distribution experiments in healthy mice
For tissue distribution experiments, male Swiss albino
mice were each injected with a 100-μL bolus containing
[111In]AT1S or [111In]AT2S (37 to 74 kBq, 10 pmol of
total peptide) via the tail vein. In the in vivo receptor
blockade animal group, excess Tate (50 nmol) was admi-
nistered intravenously (iv) together with the radioligand.
Animals were sacrificed in groups of four at 4- and 24-h
time points post injection (pi). Blood and urine were im-
mediately collected, and the organs of interest were
excised and weighed; their radioactivity content was mea-
sured in an automatic gamma counter using proper stan-
dards of the injected dose. Tissue distribution data were
calculated as percent injected dose per gram (%ID/g)
applying a suitable algorithm.
In vivo distribution experiments in AR4-2J tumor-bearing
mice
In the flanks of each of female SCID mice, inocula (150
μL) containing a suspension of 0.8 × 107 AR4-2J cells in
PBS buffer were subcutaneously injected. Tumors of
substantial size were grown within 12 days, whereupon
biodistribution experiments were performed selectively
for [111In]AT2S. Animals were injected in the tail vein19
.3
95
m of [111In]AT2S labeling reaction mixture performed on a Waters 600
in with a linear gradient of 20% B to 50% B in 30 min; A= 0.1% TFA
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74 kBq, 10 pmol of total peptide); three animals were
co-injected with excess Tate (50 nmol) together with the
radioligand (blocked animals). Mice were sacrificed at
4 h pi, and biodistribution was studied as described
above.
In vivo distribution experiments in HEK293-hsst2A
+ , -hsst3
+ or
-hsst5
+ tumor-bearing mice
In the flanks of SCID mice, inocula (150 μL) containing
a suspension of 1.8 × 107 HEK293-hsst2A
+ , -hsst3
+ or -hsst5
+
cells in PBS were subcutaneously injected. Tumors of
substantial size were grown within 3 weeks, whereupon
biodistribution experiments were performed. Animals101 nM
S
S
14
A
T
2S
10 1 nM
S
S
14
A
T
2S
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B
Figure 3 Sst2 or sst3 receptor internalization in HEK-sst2 or HEK-sst3 d
HEK-sst3 (B) cells were treated for 30 min at 37 °C with increasing concent
control) and then processed for immunofluorescence microscopy. AT2S is
receptors.were injected in the tail vein with a 100-μL bolus con-
taining [111In]AT2S (37 to 74 kBq, 10 pmol of total pep-
tide) and were sacrificed at 4 h pi; for in vivo blockade,
mice were co-injected with either excess DP2 (35 nmol;
HEK293-hsst2A
+ tumors) or with excess AT2S (35 nmol;
HEK293-hsst3
+ and -hsst5
+ tumors), and biodistribution
was conducted as described above.
Statistical analysis
The in vivo data presented as mean %ID/g ± SD (n ≥ 4)
were statistically analyzed with Student’s t test (PrismTM
2.01, GraphPad Software, San Diego, CA, USA). Ana-
lyses were 2-tailed, and a P value< 0.05 was considered
statistically significant.100 nM
 nM
nM
100 nM
etermined by immunofluorescence microscopy. HEK-sst2 (A) or
rations ranging between 1 and 100 nM of either AT2S or SS14 (positive
an agonist at sst2 and sst3 since it stimulates internalization of both
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Figure 4 Comparative internalization of [111In]AT1S and [111In]
AT2S in AR4-2J cells. (A) Internalized fraction calculated versus cell-
associated activity and (B) internalized fraction calculated per million
cells versus total added radioactivity; nonspecific internalization, as
determined in the presence of 1 μM Tate in the medium, is
indicated by dashed lines.
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Results
Synthesis of conjugates
The linear amino acid AT1S and AT2S sequences were
assembled on the solid support applying the Fmoc/tBu
methodology, and the DOTA-protected chelator was
coupled at the N-terminus. The DOTA-peptide conju-
gates were cleaved from the solid support, and the lat-
eral protecting groups were removed by TFA treatment.
Cyclization was conducted with iodine oxidation in solu-
tion and was monitored by analytical HPLC. The
cyclized products (Figure 1) were isolated by semi-pre-
parative HPLC and lyophilized. Product purity was
assessed by analytical HPLC; ES-MS data were consist-
ent with the expected formula (Table 1).
Radiolabeling
Labeling of ATIS and AT2S with 111In (Figure 1) was
achieved by a 20-min incubation of the analogs in acidic
medium at 90 °C in the presence of 111InCl3, according
to published protocols [13,44]. A >96% radiometal in-
corporation was typically shown by HPLC analysis on an
RP column; a representative radiochromatogram of
[111In]AT2S quality control is shown in Figure 2.
Determination of hsst1-5 profile
The IC50 values of ATIS and AT2S for all five somato-
statin receptor subtypes are summarized in Table 2. Data
were acquired by receptor autoradiography assays in
cells selectively expressing one of the five hsst1-5; [Leu
8,
DTrp22,125I-Tyr25]SS28 was used as pansomatostatin
radioligand and SS14 and SS28 as controls. Both ana-
logs, AT1S and AT2S, exhibit a clear pansomatostatin
profile with a high affinity binding to all five hsst1-5.
However, AT1S and AT2S show a slightly lower affinity
for sst1 and sst5 compared with the natural somatosta-
tins, SS14 and SS28.
Sst2- and sst3-internalization assay
The ability of AT2S to stimulate sst2 or sst3 internalization
in HEK-sst2 and HEK-sst3 cells was analyzed using an im-
munofluorescent-based internalization assay. Figure 3 illus-
trates that AT2S exhibits similar agonistic properties as the
natural SS14 for sst2 (Figure 3A) and for sst3 (Figure 3B) in
respect of stimulating receptor internalization.
Internalization of radioligands
The internalization properties of the radiopeptides [111In]
AT1S and [111In]AT2S were studied in rsst2A
+ AR4-2J cells
at 37 °C with or without excess Tate. The internalization
of both analogs was rapid and rsst2A-mediated, as shown
by the significant decrease of internalization levels mani-
fested in the presence of excess Tate (Figure 4A,B). More
than 75% of cell-associated activity internalized within30 min remaining at this level up to 2 h for both radiopep-
tides (Figure 4A). At 120 min, 5% and 10% of the total
added radioactivity internalized for [111In]AT1S and
[111In]AT2S, respectively, revealing a significantly more ef-
ficient internalization process for the DTrp8 analog
(Figure 4B).
Metabolism in blood
Both [111In]AT1S and [111In]AT2S showed suboptimal
stability in the blood stream of healthy mice. As evi-
denced by HPLC analysis of murine blood collected
5 min after injection of the radioligands, both analogs
degraded to at least one major radiometabolite eluting
with the solvent front. Traces of additional metabolites
having different elution patterns for the two analogs
were also observed (Figure 5A,B). The DTrp8 containing
radiopeptide showed higher metabolic stability with 6.5%
of intact [111In]AT2S still detected in this period versus
only 2% of [111In]AT1S found intact under the same
conditions. The tR of the intact analogs was established
B6%
A
2%
C D
Figure 5 Comparative in vivo stability of [111In]AT1S and [111In]AT2S. Analysis by HPLC of murine blood collected 5 min after injection of
(A) [111In]AT1S and (B) [111In]AT2S. Co-injection with (C) [111In]AT1S and (D) [111In]AT2S radioligands show the tR of the respective intact
radiopeptides. Analyses were performed on a Waters 600 HPLC system with a Symmetry Shield RP18 column eluted at a flow rate of 1 mL/min
with a linear gradient of 0% B to 50% B in 50 min, with A = 0.1% TFA (v/v) and B =MeCN; the position of original peptide elution is indicated by
the arrow, and the number by the arrow shows the percentage (%) of intact peptide detected in the blood.
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tered in mice (Figure 5C,D, respectively).
Biodistribution in healthy mice
Tissue distribution data of [111In]AT1S and [111In]AT2S
in healthy male Swiss albino mice for the 4- and 24-h
time points are summarized as %ID/g in Figure 6A,B, re-
spectively. Both analogs showed a rapid clearance from
blood and background tissues with minimal residual ac-
tivity in pool organs. [111In]AT1S failed to show specific
uptake in the sst2-rich pancreas (<0.5%ID/g at 4 h pi) in
contrast with [111In]AT2S, which clearly showed recep-
tor-specific uptake in this organ (2.9%ID/g at 4 h pi ver-
sus 0.17%ID/g at 4 h pi + excess Tate) as well as in the
stomach and intestines. On the other hand, kidney up-
take was unfavorably higher for [111In]AT2S (22.9%ID/g
versus 10.9%ID/g for [111In]AT1S at 4 h pi). However,
renal values declined over time for both analogs, reach-
ing comparable levels at 24 h pi (6.6%ID/g for [111In]
AT1S and 7.6%ID/g for [111In]AT2S).
Biodistribution in AR4-2J tumor-bearing mice
Results of [111In]AT2S tissue distribution in SCID mice
bearing AR4-2J experimental tumors are included in
Table 3, as %ID/g at 1 and 4 h pi. Biodistribution data in
SCID mice were consistent to the findings of healthy
mice tissue distribution with specific uptake shown in
the pancreas (5.13%ID/g versus 0.15%ID/g + excess Tateat 4 h pi) and the gastrointestinal tract. Uptake in the
rsst2A
+ tumor was shown to be specific as well, as sug-
gested by the significantly reduced tumor values found
during co-injection of excess Tate (1.82%ID/g at 4 h ver-
sus 0.21%ID/g + excess Tate at 4 h pi).
Biodistribution in HEK293-hsst2A
+ , -hsst3
+ or -hsst5
+ tumor-
bearing mice
In SCID mice bearing HEK293-hsst2A
+ , -hsst3
+ or -hsst5
+
tumors, [111In]AT2S showed similar biodistribution in
all organs, as indicated in Table 3. High and specific up-
take was observed in both hsst2A
+ (1.49%ID/g versus
0.27%ID/g + excess DP2 at 4 h pi) and -hsst3
+ tumors
(1.24%ID/g versus 0.32%ID/g + excess AT2S at 4 h pi).
In the HEK293-hsst5
+ tumors, the uptake was lower
(0.41%ID/g versus 0.22%ID/g + excess AT2S at 4 h pi), a
finding consistent with the lower affinity of AT2S for the
hsst5
+ (12 ± 2 nM) found in vitro (Table 2).
Discussion
The success of OctreoScanW and related cyclic octapeptide
sst2-seeking radioligands in the diagnosis and treatment of
certain human tumors relies both on their high metabolic
stability and on the prevalence and high density of sst2 ex-
pression in these tumors [11-19]. Soon, it became appar-
ent that sst2-mediated internalization of radioligands into
cancer cells represents a key element for the success of
this strategy. Intracellular accumulation of the radiolabel
BA
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0
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4 h
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%
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0
5
10
15
20
25
4 h
4 h + 50 nmol Tate
24 h
%
 ID
/g
Figure 6 Biodistribution data of (A) [111In]AT1S and (B) [111In]
AT2S. Data are acquired at 4 and 24 h after iv injection of [111In]
AT1S and [111In]AT2S in healthy male Swiss albino mice. Data are
given as mean of %ID/g ± SD, n≥ 4 per time point; for the in vivo
sst2 blockade group at 4 h pi, animals received 50 nmol Tate along
with the radioligand. Bl, blood; Li, liver; He, heart; Ki, kidneys; St,
stomach; In, intestines; Sp, spleen; Mu, muscle; Lu, lung; Fe, femur;
and Pa, pancreas.
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tumoricidal responses.
On the other hand, recent studies have reported not
only on the concomitant expression of at least one alter-
native sst1-5 subtype in tumors already expressing the
sst2, but also in tumors devoid of sst2 expression
[6,7,15,20-26]. This finding provides the opportunity to
use radiolabeled somatostatin analogs with an extended
sst1-5 affinity profile, which will consequently interact
with more binding sites on the tumor than those limited
to sst2. In this way, the diagnostic and therapeutic indi-
cations will be broadened to include more tumor types,
while diagnostic sensitivity and therapeutic efficacy will
improve. Such ‘pansomatostatin-like’ radioligands should
possess sufficient metabolic stability to be able to reach
their target after entry into the bloodstream. At the same
time, their capacity to internalize in sst2
+-cancer cells
should not be compromised in order to promote accu-
mulation in most sst1-5
+ -human tumors whereby sst2expression is dominant [27-30]. It is interesting to note
that pansomatostatin-like radioligands failing to
internalize after binding to sst2 in vivo indeed showed
poor uptake in sst2
+ tissues in mouse models [31,32]. On
the other hand, multi-sst affine and well sst2-internaliz-
ing radioligands, such as radiolabeled DOTA-NOC [33],
are expected to miss sst1-expressing tumors in patients
[23-26].
The above requirements prompted us to consider the
use of native SS14 for radioligand development. It is
interesting to note that a SS14-derived radiopeptide,
111In-[DTPA,DAla1,DTrp8,Tyr11]SS14, was previously
studied in healthy mice and compared to OctreoScanW
[34]. This analog displayed a pansomatostatin-like profile
and showed equivalent to OctreoScanW levels of specific
uptake in key target organs, such as the pituitary, the
pancreas, and the adrenals, implying that SS14-based
radioligands do have opportunities of good sst-targeting
in vivo, including the sst2. No other information on simi-
lar SS14-based radiopeptides is available.
Therefore, we have decided to couple DOTA to the N-
terminus of native and non-modified SS14. In this way,
AT1S was first generated with the purpose to serve as a
lead compound to future structurally modified pansoma-
tostatin-like radiopeptides and as a landmark for their
biological evaluation. The universal chelator DOTA has
been selected over DTPA with the aim to broaden label-
ing options beyond 111In to numerous other medically
attractive bi- and trivalent radiometals. Coupling of
DOTA on the Ala1 primary amine of SS14 inadvertently
leads to N-terminal capping of the peptide chain as well,
a strategy often pursued to increase metabolic stability
of peptides. In the second analog, AT2S, Trp8 was fur-
ther substituted by DTrp8 in our AT1S motif to convey
additional metabolic stability. This modification is
reported to also facilitate the β-turn conformation of
several cyclic somatostatin analogs leading to enriched
affinity for the sst2 [35,36].
Both AT1S and AT2S exhibited a pansomatostatin-like
in vitro profile, binding to all five sst1-5 with affinities in
the lower nanomolar range. The presence of DOTA at
the N-terminus has caused minor affinity losses for all
subtypes, which were more pronounced for sst1 and sst5.
A similar trend was also observed for [DTPA,DAla1,
DTrp8,Tyr11]SS14. Of particular interest is the ability of
AT2S to induce sst2 and sst3 internalization in vitro, as
evidenced by immunofluorescence microscopy. This ag-
onistic behavior for both, sst2 and sst3, subtypes is simi-
lar to native SS14 as it is elicited at comparable
concentration levels (10 nM). In agreement to this
finding, [111In]AT1S and [111In]AT2S internalized in
AR4-2J cells by a sst2-mediated process. Within 30 min
at 37 °C, 80% of cell bound activity was found within
the cells. It is interesting to note that [111In]AT2S
Table 3 Cumulative biodistribution data of [111In]AT2S in AR4-2J and HEK293-hsst2A
+ , -hsst3
+, and -hsst5
+ tumor-bearing
SCID mice
[111In]AT2S (%ID/g tissue± SD)
Organs AR4-2J HEK293-hsst2A
+ HEK293-hsst3
+ HEK293-hsst5
+
1 h 4 h 4 h+Tatea 4 h 4 h+DP2b 4 h 4 h+AT2Sc 4 h 4 h+AT2Sc
Blood 1.34 ± 0.21 0.19 ± 0.02 0.26 ± 0.03 0.23 ± 0.07 0.66 ± 0.35 0.19 ± 0.03 0.2 ± 0.10 0.1 ± 0.04 0.23 ± 0.03
Liver 1.27 ± 0.09 0.95 ± 0.21 1.02 ± 0.11 1.31 ± 0.36 0.963 ± 0.67 1.02 ± 0.19 1.09 ± 0.2 1.1 ± 0.08 1.25 ± 0.09
Heart 0.67 ± 0.12 0.18 ± 0.05 0.17 ± 0.04 0.22 ± 0.05 0.38 ± 0.10 0.15 ± 0.04 0.15 ± 0.01 0.15 ± 0.02 0.18 ± 0.03
Kidneys 23.83 ± 4.28 21.10 ± 4.43 24.41 ± 9.15 23.20 ± 7.04 25.51 ± 3.70 23.42 ± 4.69 23.55 ± 8.96 24.12 ± 1.21 24.68 ± 2.20
Stomach 3.23 ± 0.77 1.81 ± 0.47 0.18 ± 0.07*** 1.96 ± 0.53 1.29 ± 0.36 3.41 ± 0.97 0.19 ± 0.05*** 3.06 ± 0.73 0.17 ± 0.2***
Intestines 1.98 ± 0.29 1.92 ± 0.25 0.77 ± 0.58* 2.00 ± 0.48 1.74 ± 1.02 2.39 ± 0.43 0.54 ± 0.2*** 1.54 ± 0.09 0.57 ± 0.20***
Spleen 0.84 ± 0.21 1.10 ± 0.63 0.61 ± 0.18 0.46 ± 0.11 0.50 ± 0.36 0.82 ± 0.11 0.98 ± 0.23 0.78 ± 0.07 1.08 ± 0.16
Muscle 0.22 ± 0.02 0.06 ± 0.01 0.07 ± 0.01 0.07 ± 0.02 0.07 ± 0.03 0.06 ± 0.01 0.07 ± 0.02 0.06 ± 0.01 0.06 ± 0.02
Lung 2.05 ± 0.52 1.43 ± 1.36 3.30 ± 4.93 1.37 ± 0.55 0.47 ± 0.08 0.68 ± 0.29 0.73 ± 0.14 0.56 ± 0.28 0.83 ± 0.13
Femur 0.49 ± 0.12 0.40 ± 0.24 0.19 ± 0.02 0.24 ± 0.09 0.21 ± 0.11 0.23 ± 0.03 0.23 ± 0.04 - -
Pancreas 7.35 ± 0.74 5.13 ± 0.75 0.15 ± 0.05** 5.73 ± 1.28 0.16 ± 0.10*** 3.33 ± 0.4 0.11 ± 0.01*** 2.79 ± 0.4 0.43 ± 0.54***
Tumor 3.05 ± 0.51 1.82 ± 0.36 0.21 ± 0.17*** 1.49 ± 0.2 0.27 ± 0.20*** 1.24 ± 0.27 0.32 ± 0.06*** 0.41 ± 0.12 0.22 ± 0.006*
*Significant (p< 0.05), and ** and ***highly significant (p< 0.005) difference between blocked and unblocked animals (Student’s t test). aCo-injection of 50 nmol
Tate; bco-injection of 35 nmol DP2; cco-injection of 35 nmol AT2S.
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as compared with [111In]AT1S. This difference in
internalization rates is reflected in dissimilar uptake of
the two radioligands in sst2
+ organs after injection in
mice (vide infra).
The metabolic fate of [111In]AT1S and [111In]AT2S
was followed 5 min after entry in the bloodstream of
mice and revealed their susceptibility to enzymatic deg-
radation. [111In]AT1S was almost totally degraded within
this period, despite the N-terminal capping conveyed by
the 111In-DOTA moiety, as compared with native SS14.
By Trp8/DTrp8 substitution in [111In]AT2S, the percent-
age of integer radiopeptide increased threefold while the
pattern of detected metabolites changed. These differ-
ences, albeit small, may have a significant impact on bio-
distribution in the case where blood clearance and target
delivery rates are fast enough to compensate, at least in
part, rapid degradation rates. It is interesting to note that
after injection in healthy mice, only [111In]AT2S achieves
to specifically target sst-binding organs, such as the pan-
creas, as revealed by co-injection of excess Tate. Pancre-
atic values remained unchanged from 1 to 24 h pi,
whereas renal values substantially declined during this
period. In contrast, [111In]AT1S failed to show any
measurable specific uptake, most probably as a result of
its slower sst2-mediated internalization combined with
its poorer in vivo stability. Accordingly, further evalu-
ation in tumor-bearing mice was focused on [111In]
AT2S.
In mice bearing AR4-2J tumors spontaneously expres-
sing the rat sst2, [
111In]AT2S showed clear specific up-
take both in the experimental tumor and in the gut,including the pancreas, stomach, and intestines, as con-
firmed by suitable in vivo sst2 blockade with excess of
sst2-selective Tate. Similarly high and specific uptake was
observed in HEK-hsst2A
+ and HEK-sst3
+ tumors at 4 h pi,
although the affinity of AT2S for the hsst2A was slightly
higher as for the hsst3, and AT2S showed a similar agon-
istic capacity in triggering the internalization of both
subtypes in vitro. On the other hand, [111In]AT2S
showed a much lower, although still specific, uptake in
the HEK-hsst5
+ implants. This decrease may be attributed
to its 10-fold lower affinity for hsst5. It should be
stressed, however, that individual hsst-expression levels
on transfected HEK cells may be different, thereby
affecting radioligand uptake.
Conclusions
In summary, native SS14 and its DTrp8 analog were
functionalized with the universal chelator DOTA to
allow for labeling with most interesting diagnostic and
therapeutic radiometals. The respective AT1S prototype
and its DTrp8 derivative, AT2S, were labeled with 111In,
and several in vitro and in vivo properties of resulting
(radio)ligands were investigated. According to the data
obtained, both AT1S and AT2S show a pansomatostatin-
like affinity profile, and AT2S displays a clear agonistic
character for hsst2 and hsst3 in vitro. In contrast with
previously reported pansomatostatin-like radioligands
showing poor sst2-related internalization, [
111In]AT1S
and [111In]AT2S do internalize in AR4-2J cells via a
sst2-mediated mechanism. This parameter is promising
for in vivo application, and it was more pronounced for
[111In]AT2S. Furthermore, after injection in mice, [111In]
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physiological somatostatin binding sites, such as the
pancreas. Likewise, [111In]AT2S specifically localized in
experimental tumors in SCID mice which selectively
expressed one of sst2 (both of rat and human origin),
hsst3, or hsst5. To our knowledge, this is the first com-
prehensive study that systematically explores strengths
and weaknesses of employing native SS14-derived radi-
oligands for nuclear oncology applications. It has
demonstrated that the AT1S lead structure is promising
for radioligand development owing to its pansomatosta-
tin character and its preserved agonistic properties, es-
pecially regarding sst2 internalization. Furthermore, it
has revealed the feasibility of structural modifications to
enhance metabolic stability in order to achieve higher
tumor uptake. The body of data so far acquired will
serve as a landmark in the evaluation of innovative
structural interventions on the AT1S lead structure,
such as key amino acid replacements and/or changes of
ring size, which are currently pursued.
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